Campion, A,Casey, PG,Field, D,Cotter, PD,Hill, C,Ross, RP

2013

February

BMC Microbiology

In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice

Validated

WOS: 47 ()

Antimicrobial Lantibiotic Bacteriocin Peptide engineering Mutagenesis Nisin RESISTANT STAPHYLOCOCCUS-AUREUS GRAM-POSITIVE PATHOGENS LACTOCOCCUS-LACTIS ANTIMICROBIAL PEPTIDES ENHANCED ACTIVITY PORE FORMATION LANTIBIOTICS BIOSYNTHESIS ANTIBIOTICS VITRO

13

Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 x 10(5) cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.

10.1186/1471-2180-13-23